Company news

Kiniksa Pharmaceuticals International, plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404

November 29, 2020

Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference

November 23, 2020

Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis

November 22, 2020

Kiniksa Announces New England Journal of Medicine Publication of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020

November 16, 2020

Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis

November 15, 2020

Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data

November 8, 2020

Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity

November 4, 2020

Kiniksa Announces Phase 2 Clinical Data from Vixarelimab in Prurigo Nodularis to be Presented at European Academy of Dermatology and Venereology Virtual Congress

October 28, 2020

Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020

October 25, 2020

Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis

October 5, 2020

Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th

September 23, 2020

Kiniksa Announces Upcoming Rilonacept Analyst Day

September 20, 2020

Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis

September 14, 2020

Kiniksa Pharmaceuticals to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

September 8, 2020

Kiniksa Presents Data on the Burden of Disease in Patients with Recurrent Pericarditis at the European Society of Cardiology Congress 2020

August 30, 2020

Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference

August 3, 2020

Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity

July 29, 2020

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering

July 20, 2020

Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering

July 19, 2020

Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis

July 15, 2020

Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)

June 28, 2020

Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19

June 16, 2020

Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts

June 9, 2020

Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial

June 7, 2020

Kiniksa Pharmaceuticals to Present at 41st Annual Goldman Sachs Global Healthcare Conference

June 3, 2020

Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020

May 28, 2020

Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 17, 2020

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering

May 12, 2020

Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus

May 10, 2020

Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity

April 27, 2020

Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint

April 21, 2020

Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation

March 30, 2020

Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session

March 29, 2020

Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity

February 25, 2020

Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts

January 12, 2020

Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma

December 10, 2019

Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference

December 9, 2019

Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference

November 19, 2019

Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis

November 19, 2019

Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019

November 15, 2019

Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting

November 11, 2019

Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity

October 27, 2019

Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research

September 18, 2019

← Newer news releases

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 25 decks. Every deck is listed under its year.